Related Experiment Videos
Calcium channel blockers in heart failure
1Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.
Journal of the American College of Cardiology
|October 1, 1993
Summary
Calcium channel blockers show limited benefit and potential harm in chronic heart failure patients. Studies indicate risks of worsening heart failure and cardiac events, necessitating careful consideration of their use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers (CCBs) are considered for chronic heart failure (CHF) due to vasodilatory and anti-ischemic properties.
- Potential benefits include improved diastolic function and prevention of myocardial dysfunction in animal models.
Purpose of the Study:
- To evaluate the efficacy and safety of CCBs in patients with chronic heart failure.
- To review the outcomes of CCB therapy in various patient cohorts with heart failure.
Main Methods:
- Review of clinical studies and controlled trials involving CCBs (nifedipine, diltiazem, verapamil) in CHF patients.
- Analysis of hemodynamic profiles, clinical status, and cardiac events.
Main Results:
- Nifedipine showed initial hemodynamic improvements but led to worsening heart failure in up to 29% of patients.
- Diltiazem had less myocardial depression but long-term use in post-MI patients increased cardiac events and mortality.
- Verapamil lost its protective effect in patients with clinical heart failure.
Conclusions:
- CCBs have variable and often negative effects on chronic heart failure outcomes.
- Strategies to improve CCB safety, such as using newer agents or combination therapy, yielded mixed results.
- Careful patient selection and risk-benefit assessment are crucial when considering CCBs for heart failure.